Bioverativ’s Alprolix Found Safe and Effective in Children Under 12

Bioverativ has reported results from their ongoing Phase III trial of Alprolix in children under 12.  Thirty patients under 12 (median, 5 years of age) received once-weekly infusions of Alprolix.  Overall, 80% of patients were able to reduce their infusion frequency from that on their previous product.  The mean half-life was 68.6 hours.  Ten patients reported no bleeding and 19 patients exhibited no joint bleeding.  Four patients experienced severe adverse events, but no inhibitor development was observed.